



## Model List of Essential Medicines



### **Alfacalcidol** [General information](#)

Section

Medicines for endocrine disorders

- Oral > Liquid: 2 µg per mL
- Oral > Solid > capsule: 0.25 µg; 1 µg

Indications

[Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport](#)



### **Beinaglutide** [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#)



### **Bromocriptine** [General information](#)

Section

Medicines for disorders of the pituitary hormone system

Indications

Therapeutic equivalent to [cabergoline](#) for [Other specified benign neoplasm of endocrine glands](#)



### **Cabergoline** [General information](#)

Section

Medicines for disorders of the pituitary hormone system

- Oral > Solid > tablet: 0.5 mg; 1 mg

Indications

[Other specified benign neoplasm of endocrine glands](#)



### **Calcitriol** [General information](#)

Section

Medicines for endocrine disorders

- Oral > Solid > capsule: 0.25 µg; 0.5 µg

Indications

[Chronic kidney disease, stage unspecified Disorders of vitamin D metabolism or transport](#)



### **Canagliflozin** [General information](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [empagliflozin](#) for [Type 2 diabetes mellitus](#)

**Carbimazole [General information](#)**

Section

Thyroid hormones and antithyroid medicines

Indications

Therapeutic equivalent to [methimazole](#) for [Thyrotoxicosis](#)

**Dapagliflozin [General information](#)**

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [empagliflozin](#) for [Type 2 diabetes mellitus](#)

**Diazoxide [General information](#)**

Section

Medicines for hypoglycaemia

- Oral > Liquid: 50 mg per mL
- Oral > Solid: 50 mg

Indications

[Persistent hyperinsulinaemic hypoglycaemia of infancy](#)

**Dulaglutide [General information](#)**

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#) Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

**Empagliflozin [General information](#)**

Section

Hypoglycaemic agents

- Oral > Solid: 10 mg; 25 mg

Indications

[Type 2 diabetes mellitus](#)

**Estradiol [General information](#)**

Section

Estrogens

- Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

Indications

[Hypopituitarism](#) [Gonadotropin deficiency](#) [Turner syndrome](#)

**Exenatide [General information](#)**

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#)

**Fludrocortisone [General information](#)**

Section

Adrenal hormones and synthetic substitutes

- Oral > Liquid: 100 µg per mL

- Oral > Solid > tablet: 100 µg (acetate)

Indications

[Adrenocortical insufficiency](#)

#### **Glibenclamide** [General information](#)

Section

Hypoglycaemic agents

- Oral > Solid: 5 mg; 2.5 mg

Indications

[Type 2 diabetes mellitus](#)

#### **Gliclazide** [General information](#)

Section

Hypoglycaemic agents

- Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

Indications

[Type 2 diabetes mellitus](#)

#### **Glucagon** [General information](#)

Section

Medicines for hypoglycaemia

- Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

Indications

[Hypoglycaemia in the context of diabetes](#)

#### **Hydrocortisone** [General information](#)

Section

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 5 mg; 10 mg; 20 mg
- Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule

Indications

[Adrenocortical insufficiency](#)

#### **Insulin (analogue, long-acting)** [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

#### **Insulin (analogue, rapid-acting)** [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen

Indications

[Type 1 diabetes mellitus](#) [Type 2 diabetes mellitus](#)

#### **Insulin (human, intermediate-acting)** [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

**Insulin (human, short-acting) [General information](#)**

Section

Insulins

- Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

**Insulin analogues [General information](#)**

Section

Insulins

- Not specified

Indications

[Type 2 diabetes mellitus](#) [Type 1 diabetes mellitus](#)

**Insulin aspart [General information](#)**

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen
- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 2 diabetes mellitus](#)

**Insulin degludec [General information](#)**

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

Therapeutic equivalent to [insulin glargine](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)

**Insulin detemir [General information](#)**

Section

Insulins

Indications

Therapeutic equivalent to [insulin glargine](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)

**Insulin glargine [General information](#)**

Section

Insulins

- Parenteral > General injections > SC: 100 units per mL

Indications

[Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 2 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, long-acting\)](#) for [Type 1 diabetes mellitus](#)

**Insulin glulisine [General information](#)**

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 2 diabetes mellitus](#)

**Insulin lispro** [General information](#)

Section

Insulins

- Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 1 diabetes mellitus](#) Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for [Type 2 diabetes mellitus](#)

**Iodine + potassium iodide (Lugol's solution)** [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Liquid: 5% w/v + 10% w/v (aqueous)

Indications

[Thyrotoxicosis](#)

**Ketoconazole** [General information](#)

Section

Medicines for endocrine disorders

- Oral > Solid > tablet: 200 mg

Indications

[Cushing syndrome](#)

**Levothyroxine** [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)

Indications

[Hypothyroidism](#)

**Liraglutide** [General information](#)

Section

Medicines for endocrine disorders

- Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

Indications

[Obesity](#)

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#) Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

**Medroxyprogesterone acetate** [General information](#)

Section

Progestogens

- Oral > Solid: 5 mg

Indications

[Excessive menstruation with irregular cycle](#)

**Metformin** [General information](#)

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg (hydrochloride)

Indications

[Type 2 diabetes mellitus](#)

**Methimazole** [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 5 mg; 10 mg

Indications

[Thyrotoxicosis](#)

**Norethisterone** [General information](#)

Section

Progestogens

- Oral > Solid: 5 mg

Indications

[Excessive menstruation with irregular cycle](#) Therapeutic equivalent to [medroxyprogesterone acetate](#) for [Excessive menstruation with irregular cycle](#)

**Octreotide** [General information](#)

Section

Medicines for disorders of the pituitary hormone system

- Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent
- Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate)

Indications

[Acromegaly or pituitary gigantism](#)

**Phosphorus** [General information](#)

Section

Medicines for endocrine disorders

- Oral > Other: 500 mg in sachet (elemental phosphorus) granules
- Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

Indications

[Hypophosphataemic rickets](#)

**Potassium iodide** [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid > tablet: 65 mg (scored)

Indications

[Thyrotoxicosis](#)

**Prednisolone** [General information](#)

Section

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 1 mg

Indications

[Adrenocortical insufficiency](#)

**Prednisone** [General information](#)

Section

Adrenal hormones and synthetic substitutes

- Oral > Solid > tablet: 1 mg

Indications

Therapeutic equivalent to [prednisolone](#) for [Adrenocortical insufficiency](#)

**Propylthiouracil** [General information](#)

Section

Thyroid hormones and antithyroid medicines

- Oral > Solid: 50 mg

Indications

[Thyrotoxicosis](#)

**Semaglutide [General information](#)**

Section

Hypoglycaemic agents

- Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution
- Oral > Solid > tablet: 3 mg
- Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

Indications

[Obesity Type 2 diabetes mellitus](#)

**Simvastatin [General information](#)**

Section

Medicines for endocrine disorders

- Oral > Solid: 20 mg

Indications

[Polycystic ovary syndrome](#)

**Somatropin [General information](#)**

Section

Medicines for endocrine disorders

- Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge

Indications

[Hypoglycaemia without associated diabetes](#)

**Testosterone [General information](#)**

Section

Androgens

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate)

Indications

[Testicular dysfunction or testosterone-related disorders](#)

**Tirzepatide [General information](#)**

Section

Hypoglycaemic agents

Indications

Therapeutic equivalent to [semaglutide](#) for [Obesity](#) Therapeutic equivalent to [semaglutide](#) for [Type 2 diabetes mellitus](#)

**Tolbutamide [General information](#)**

Section

Hypoglycaemic agents

- Oral > Solid: 500 mg

Indications

[Type 2 diabetes mellitus](#)

**Zoledronic acid [General information](#)**

Section

Medicines for endocrine disorders

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

[Osteogenesis imperfecta](#)